10-Q: BioRestorative Therapies Q1 2026 Results: Net Loss Narrows, Cash Position Strengthens

BioRestorative Therapies, Inc. reported a narrowed net loss for Q1 2026, improved working capital, and a strengthened cash position, though it faces Nasdaq minimum bid price non-compliance.

Summary

• BioRestorative Therapies, Inc. reported a net loss of $2.15 million for the first quarter ended March 31, 2026, a significant improvement from a net loss of $5.34 million in the same period of 2025.
• Total revenues for Q1 2026 were $23,170, a slight decrease from $25,000 in Q1 2025, with product revenue of $11,870 from the new BioX line and $11,300 in royalty revenue.
• Operating expenses decreased by 29.6% to $3.40 million in Q1 2026 from $4.83 million in Q1 2025, primarily due to reduced research and development and general administrative costs.
• The company's cash and cash equivalents increased to $3.11 million as of March 31, 2026, from $1.51 million as of December 31, 2025.
• Working capital improved significantly to $2.19 million from a deficit of $0.59 million, largely due to the reclassification of warrant liabilities to equity.
• The company received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and has until September 22, 2026, to regain compliance.
• The company has material weaknesses in its internal control over financial reporting, including a lack of adherence to formal policies and procedures and insufficient risk assessment.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the Nasdaq non-compliance, going concern doubts, and material weaknesses in internal controls, despite some operational improvements.

Positives

• Net loss significantly reduced to $2.15 million in Q1 2026 from $5.34 million in Q1 2025.
• Operating expenses decreased by 29.6% to $3.40 million in Q1 2026.
• Cash and cash equivalents increased by $1.60 million to $3.11 million.
• Working capital improved from a deficit of $586,029 to a positive $2,185,071.
• Successfully completed a public offering (Rodman Offering) raising approximately $5.0 million in gross proceeds.
• Series B Convertible Preferred Stock was fully converted into common stock, simplifying the capital structure.
• The company's lead product candidate, BRTX-100, is progressing in Phase 2 clinical trials with a positive recommendation from the Data Safety Monitoring Board to continue without changes.

Negatives

• Total revenues decreased slightly to $23,170 in Q1 2026 from $25,000 in Q1 2025.
• Royalty revenue decreased by 54.8% due to fewer disc procedures.
• The company received a non-compliance notice from Nasdaq for failing to meet the minimum bid price requirement ($1.00 per share).
• The company has material weaknesses in its internal control over financial reporting, impacting disclosure controls and procedures.
• The company's current funds are not sufficient to complete development activities or achieve profitable operations, raising substantial doubt about its ability to continue as a going concern.
• The company may need to curtail development, marketing, and promotional activities if additional financing is not obtained.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement by September 22, 2026, could lead to delisting.
• Substantial doubt exists about the company's ability to continue as a going concern due to ongoing net losses and negative cash flows from operations.
• The company's ability to obtain necessary financing to complete clinical trials and implement its business plan is critical.
• Risks associated with the development and commercialization of BRTX-100, ThermoStem Program, and biocosmeceutical products.
• The company's reliance on a single customer for all royalty revenue and for ExoCR product sales presents concentration risk.
• Material weaknesses in internal controls over financial reporting could lead to misstatements in financial reporting.
• The company may be unable to attract and retain key scientific, technological, and management personnel.

Future Outlook

The company anticipates continuing to incur net losses and negative cash flows from operations as it executes its development plans and other strategic initiatives. Its current funds are not sufficient to complete development activities or achieve profitable operations, necessitating future financing. The company intends to monitor its stock price and consider options to regain Nasdaq compliance, including a reverse stock split.

Management Comments

• The company's current funds will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company's business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.
• We intend to monitor the closing bid price of our Common Stock and consider our available options to resolve the noncompliance with the minimum bid price requirement, including effecting a reverse split of our Common Stock.
• Management is committed to maintaining a strong internal controls environment and implementing measures designed to help ensure that control deficiencies contributing to the material weaknesses are remediated as soon as possible.

Industry Context

StockSavvy.ai notes that BioRestorative Therapies operates in the highly competitive and capital-intensive biotechnology sector, where clinical trial success, regulatory approvals, and continuous funding are paramount. The company's focus on cell and tissue protocols, particularly for disc/spine disorders and metabolic conditions, places it in areas with significant unmet medical needs but also substantial scientific and commercialization challenges. The Nasdaq non-compliance issue is a common hurdle for early-stage biotech firms struggling to maintain market capitalization thresholds.

Comparison to Industry Standards

• The company's net loss of $2.15 million for the quarter is substantial for its revenue of $23,170, indicating a high burn rate typical of early-stage biotech companies investing heavily in R&D. For comparison, companies like Moderna (MRNA) or BioNTech (BNTX) in their early stages also reported significant losses while advancing pipeline candidates.
• The decrease in R&D expenses by 27.2% year-over-year, while potentially a positive for short-term cash conservation, could raise concerns if it signifies a slowdown in critical development activities for BRTX-100 or the ThermoStem Program.
• The company's cash position of $3.11 million, while improved, is modest for a company in clinical development, especially considering the ongoing need for substantial funding to advance its programs through later-stage trials and potential commercialization. Industry benchmarks suggest that companies at similar stages often require hundreds of millions of dollars.
• The Nasdaq minimum bid price issue is a common challenge. Many small-cap biotech companies face this and often address it through reverse stock splits, which can be viewed negatively by the market if not accompanied by fundamental improvements.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq, dilution from future capital raises, and uncertainty regarding the company's going concern status.
• Employees: Potential impact on morale and job security if operations are curtailed due to lack of funding.
• Creditors: Increased risk if the company cannot meet its financial obligations.
• Customers: Continued availability of biocosmeceutical products (BioX) and potential future therapeutic products depends on the company's financial stability.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by September 22, 2026.
• Continue Phase 2 clinical trial for BRTX-100.
• Advance research for the ThermoStem Program.
• Continue commercial sales of BioX product line and pursue sales for ExoCR.
• Implement remediation plan for material weaknesses in internal controls.
• Seek additional financing to fund operations and development.

Key Dates

Recommendation

The company shows some operational improvements with a narrowed net loss and increased cash, but significant risks remain, including Nasdaq non-compliance, going concern doubts, and material weaknesses in internal controls. These factors warrant a cautious 'hold' recommendation, pending clarity on Nasdaq compliance and successful fundraising efforts.

Keywords

BioRestorative Therapies, BRTX, 10-Q, Quarterly Report, Financial Statements, Results of Operations, Net Loss, Cash Flow, Liquidity, Nasdaq Compliance, BRTX-100, Cell Therapy, Biocosmeceuticals, Stock Options, Warrants, Going Concern